Fusen Pharmaceutical Co (HKSE:01652) Total Liabilities : HK$880.8 Mil (As of Jun. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Fusen Pharmaceutical Co Total Liabilities?

Fusen Pharmaceutical Co's Total Liabilities for the quarter that ended in Jun. 2024 was HK$880.8 Mil.

Fusen Pharmaceutical Co's quarterly Total Liabilities increased from Jun. 2023 (HK$756.29 Mil) to Dec. 2023 (HK$854.81 Mil) and increased from Dec. 2023 (HK$854.81 Mil) to Jun. 2024 (HK$880.84 Mil).

Fusen Pharmaceutical Co's annual Total Liabilities increased from Dec. 2021 (HK$713.12 Mil) to Dec. 2022 (HK$823.44 Mil) and increased from Dec. 2022 (HK$823.44 Mil) to Dec. 2023 (HK$854.81 Mil).

Fusen Pharmaceutical Co Total Liabilities Historical Data

The historical data trend for Fusen Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusen Pharmaceutical Co Total Liabilities Chart

Fusen Pharmaceutical Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

691.22

713.12

823.44

854.81

928.66

Fusen Pharmaceutical Co Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial													823.44	756.29	854.81	880.84	928.66

Fusen Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Fusen Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	726.838	+	(116.457	+	11.514
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	854.8

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1469.76	-	614.951
	=	854.8

Fusen Pharmaceutical Co's Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	743.685	+	(116.651	+	20.506
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	880.8

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	1439.74	-	558.898
	=	880.8

Fusen Pharmaceutical Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Fusen Pharmaceutical Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Fusen Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fusen Pharmaceutical Co Ltd (HKSE:01652) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

Urban Industrial Zone, Henan Province, Xichuan County, Zhengzhou, CHN

Website

http://www.fusenyy.com

Fusen Pharmaceutical Co Ltd is engaged in manufacturing shuanghuanglian based cold medicine. The product portfolio company includes shuanghuanglian based cold medicines which include oral solutions and shuanghuanglian injections, other PCM and western medicine products which include compound ferrous sulphate granules and flunarizine hydrochloride capsules.

Executives

Cao Changcheng	2201 Interest of corporation controlled by you
Quan Xiufeng	2202 Interest of your spouse
Full Bliss Holdings Limited	2101 Beneficial owner
One Victory Investments Limited	2101 Beneficial owner
Cao Zhiming	2201 Interest of corporation controlled by you
Zhou Peilin	2202 Interest of your spouse
Rayford Global Limited	2306 Nominee for another person
Tct (bvi) Limited	2501 Other
The Core Trust Company Limited	2301 Trustee
First Joint Elegant Limited	2101 Beneficial owner
Fung Wai Sze	2202 Interest of your spouse
Lam Yiu Por	2201 Interest of corporation controlled by you

Fusen Pharmaceutical Co Headlines

No Headlines